71 results
8-K
EX-1.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, ANX1502 was generally well tolerated across … dose, or MAD, clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD
424B5
ANNX
Annexon Inc
4 Jun 24
Prospectus supplement for primary offering
5:21pm
, and multiple-ascending dose, or MAD, clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK … , clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, ANX1502
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
approved therapy to treat GBS.”
The clinical safety and tolerability findings of ANX005 at both doses in the Phase 3 study support a generally well … -tolerated profile with no new safety signals. The majority of adverse events were mild Grade 1 to moderate Grade 2 events. The most common treatment
8-K
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
mg/kg dose resulting in one week of C1q inhibition appeared to define the optimal treatment window.
The clinical safety and tolerability findings … of ANX005 at both doses in the Phase 3 study support a generally well-tolerated profile with no new safety signals. The majority of adverse events were
8-K
EX-99.2
24sbwem x9c
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
8-K
EX-99.1
faq9szrqk0qh3 eo
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
ynw6 1f2r
7 May 24
Other Events
4:05pm
424B5
tmee4hg0g7a7g6cwni
5 Apr 24
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
wvola
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
rsz 88pge4i
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
dvklf p5pnzno46wc
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-1.1
gysd aqn4b3o
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
424B5
hml5nnzb18e9gst9de
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.4
lptzyi7jgb
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
q4nwhk67pp6fy ai
20 Dec 23
Regulation FD Disclosure
5:17pm